Quick Comparison
| Bronchogen | Testagen | |
|---|---|---|
| Half-Life | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure |
| Typical Dosage | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Standard Khavinson pulse-dosing protocol. | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Cycling protocol consistent with the Khavinson family. |
| Administration | Oral capsule or subcutaneous injection (cycled) | Oral capsule or subcutaneous injection (cycled) |
| Research Papers | 5 papers | 2 papers |
| Categories |
Mechanism of Action
Bronchogen
Bronchogen is a Khavinson tetrapeptide (Ala-Glu-Asp-Leu) positioned as the respiratory-system bioregulator within the wider Khavinson peptide family. The proposed mechanism follows the family-wide framework: tissue-derived short peptides preferentially target the same tissue type from which they were originally identified, binding to gene promoter sequences and modulating expression of tissue-specific genes.
For bronchogen, proposed targets include genes regulating bronchial epithelial cell proliferation and differentiation, surfactant production by alveolar type II cells, ciliary function in airway epithelium, and local immune regulation in respiratory mucosa. Russian research has reported bronchogen-induced improvements in lung function markers in animal models of chronic respiratory injury and in elderly populations with age-related pulmonary decline. Cellular studies have suggested effects on mucociliary clearance and reductions in airway inflammation markers.
As with all Khavinson cytogens and cytamins, the evidence base is concentrated in Russian gerontology and pulmonology research traditions with limited independent Western validation. Bronchogen is not a substitute for evidence-based treatment of asthma, chronic obstructive pulmonary disease, or other diagnosed respiratory conditions, and its role in respiratory health should be considered exploratory rather than established. The brief plasma half-life (around 30 minutes) reflects the family-wide model of transient signalling triggering longer-lasting transcriptional effects.
Testagen
Testagen is a short Khavinson tetrapeptide (Lys-Glu-Asp-Gly) positioned as the male reproductive and prostate tissue bioregulator within the wider Khavinson peptide family. The proposed mechanism is consistent with the family-wide model: short peptides interact with gene promoter regions in target tissue cells, modulating tissue-specific gene expression patterns to support normal cellular function and counteract age-related decline.
Proposed targets include genes regulating prostate epithelial proliferation and differentiation, androgen receptor signalling sensitivity, and local immune function within prostatic and testicular tissue. Russian research groups have reported testagen-induced improvements in indices of urinary and sexual function in elderly men with age-related prostatic and testicular decline, and animal studies have suggested effects on testicular function markers and prostate gland histology.
As with all Khavinson bioregulators, the published efficacy evidence sits almost entirely within Russian gerontology research traditions and has not been replicated in independent Western randomised controlled trials. Importantly, testagen is not validated for the prevention or treatment of prostate cancer or benign prostatic hyperplasia, and its safety in men with hormone-sensitive cancers has not been established. Use should not displace evidence-based urology care, and users with prostate concerns should consult a urologist rather than relying on bioregulator protocols.
Risks & Safety
Bronchogen
Common
generally well tolerated in Russian observational studies.
Serious
very limited Western clinical data; not a substitute for evidence-based treatment of asthma, COPD, or other chronic respiratory disease.
Rare
allergic reactions.
Testagen
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; not validated for prostate cancer prevention or treatment, and any effect on hormone-sensitive tissues remains uncharacterised in rigorous trials.
Rare
allergic reactions. Should not replace evidence-based urology care.
Full Profiles
Bronchogen →
A Khavinson tetrapeptide (Ala-Glu-Asp-Leu) developed in Russia as a tissue-specific bioregulator targeting the lungs and respiratory tract. Promoted for chronic respiratory conditions, age-related decline in lung function, and recovery from respiratory illness. Like the other Khavinson cytamins, the evidence base is dominated by Russian research and not independently validated in Western clinical practice.
Testagen →
A Khavinson tetrapeptide (Lys-Glu-Asp-Gly) developed in Russia as a tissue-specific bioregulator targeting prostate and testicular tissue. Promoted for supporting age-related decline in male reproductive and urinary function. Sits in the same Khavinson family as the other tissue-specific cytogens. Western clinical evidence is limited.